ETFMG Treatments, Testing and Advancements ETF: (GERM)
(Delayed Data from NYSE) As of Feb 26, 2021 04:00 PM ET
$38.44 USD
+0.14 (0.37%)
Volume: 13,384
This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:
Zacks Rank | Definition |
---|---|
1 | Strong Buy |
2 | Buy |
3 | Hold |
4 | Sell |
5 | Strong Sell |
See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs
ETF Quote Details
Previous Close | 38.30 |
Open | 38.15 |
Bid | 38.00 |
Ask | 38.49 |
Day Low-High | 37.30-38.74 |
52wk Low-High | 23.80-44.69 |
Volume | 13,384 |
NAV (month end) | 39.34 |
Premium (+)/Discount (-) (month end) | -1.04 |
ETF Expense Ratio
Expense Ratio | 0.68% |
Dividend (Yield) | $0.28 (0.74%) |
Issuer | ETF MANAGERS |
Benchmark for GERM
PRIME TREATMENTS TESTING & ADVNCMNTS ID
The Prime Treatments, Testing and Advancements Index provides investors with a reference measure that enables them to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases.
Fund Summary for GERM
ETFMG TREATMENTS TESTING & ADVNCMNTS ETF
The ETFMG Treatments, Testing and Advancements ETF provides investment results that, before fees and expenses, correspond generally to the price and yield performance of the Prime Treatments, Testing and Advancements Index.